SEQIRUS UK LIMITED
Location
Founded
2015-05-29
Website
Risk Signals
39 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Offices of Holding Companies, Not Elsewhere Classified, Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SEQIRUS UK LIMITED
Live alerts from global media, monitored by Business Radar
2024-10-30 (stocktitan.net)
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Amarin reports mixed Q3 results: 36% revenue decline to $42.3M, but maintains $306M cash position. European VAZKEPA sales surge 19% while U.S. sales face headwinds. See detailed analysis of pharma giant's performance.
Read more
2024-10-30 (stocktitan.net)
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Amarin reports mixed Q3 results: 36% revenue decline to $42.3M, but maintains $306M cash position. European VAZKEPA sales surge 19% while U.S. sales face headwinds. See detailed analysis of pharma giant's performance.
Read more
2024-06-24 (agriland.ie)
Ireland to receive vaccines for people at higher risk of bird flu
Ireland is due to receive doses of a vaccine for people deemed to be at a higher risk of exposure to bird flu in the coming months.
Read more
2024-06-12 (agriland.ie)
EU secures 40m vaccines for people at higher risk of bird flu
The European Commission is preparing to offer vaccines to people deemed to be a higher risk of exposure to avian influenza (bird flu).
Read more
2022-12-13 (pharmaceutical-technology.com)
CSL closes mRNA vaccine deal with Arcturus
CSL Seqirus has closed the international partnership and licence agreement with Arcturus Therapeutics for sa-mRNA vaccines.
Read more
2022-12-13 (pharmaceutical-technology.com)
CSL closes mRNA vaccine deal with Arcturus
CSL Seqirus has closed the international partnership and licence agreement with Arcturus Therapeutics for sa-mRNA vaccines.
Read more
(csl.com)
CSL Seqirus secures multi-year pandemic preparedness agreement as part of its continued partnership with the UK government
CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...
Read more
(csl.com)
CSL Seqirus secures multi-year pandemic preparedness agreement as part of its continued partnership with the UK government
CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...
Read more